Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/emfGCfbwocfDlKvlxdEY

March 4, 2013News for medical technology professionals

  Top Story 
  • Mercator gains EU approval for micro-infusion catheters
    Mercator MedSystems has earned the CE mark to market its Cricket and Bullfrog micro-infusion catheters in Europe. The devices already have U.S. approval. The devices are used to deliver drugs straight to deep tissue through blood vessel walls, keeps the injected agent from spreading throughout the body while also allowing for a high concentration near the targeted area. MedGadget.com (3/1) LinkedInFacebookTwitterEmail this Story
Asian Cancer Market Set to Grow Along with Increased Disease Rates
Rates of cancer have risen dramatically in Asia, where more than six million people are diagnosed with the disease every year. That number now accounts for 50% of new global cases. According to the World Health Organization (WHO), the occurrence of cancer in India and China is set to climb to at a rate of 78% from now through 2030. Find out the details.

  Business & Market Trends 
  International Developments 
  • Global MRI market could hit $6B in five years, report says
    ReportsnReports forecasts that by 2018, the global market for MRI scanners will be valued at $6 billion, with the U.S. market expected to account for $2.1 billion. The report notes that this growth will be driven by technological developments, more clinical software being made available and the arrival of MRI-safe pacemakers, among other factors. AuntMinnie.com (free registration) (3/1) LinkedInFacebookTwitterEmail this Story
  Science & Health 
  • Trial compares heart implant, warfarin for AF patients
    In patients with atrial fibrillation, Boston Scientific's Watchman heart implant performed better than the anticoagulant warfarin in terms of quality-of-life indicators after one year, according to a study published in the Journal of the American College of Cardiology. The study, however, also found that patients who had the implant had a higher risk for serious bleeding. MassDevice.com (Boston) (2/28) LinkedInFacebookTwitterEmail this Story
  Emerging Technologies 
  Hot Topics 

Top five news stories selected by AdvaMed SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Government & Regulatory 
  • AdvaMed CEO raises concerns over fallout from sequestration
    The FDA's budget and the user fees paid by the medtech industry will be affected by the automatic budget cuts known as sequestration, said AdvaMed President Stephen Ubl, who adds that his group is working to make a case about the adverse effects of those cuts. Ubl also expressed concern that political distractions are complicating industry efforts to strike down the medical device tax. "It clearly makes it harder to focus individual members [of Congress] on the harmful impacts of the tax," he said, "[But] I think we’re off to a very strong start this year." Star Tribune (Minneapolis-St. Paul, Minn.) (3/2) LinkedInFacebookTwitterEmail this Story
 
  • FDA examines complications tied to Intuitive's surgical robot
    The FDA reportedly is conducting a survey on complications experienced by doctors in using Intuitive Surgical's da Vinci surgical robot after receiving increased incident reports tied to the device. Doctors in the survey also were asked about the training they obtained in using the technology as well as about procedures that may or may not be ideal for the device. MassDevice.com (Boston) (3/1) LinkedInFacebookTwitterEmail this Story
AdvaMed News 
  • Medical Device Tax Workshop
    Wednesday, March 13 -- Thursday, March 14
    Sheraton Crystal City, Arlington, Va.

    Join tax professionals in discussing how to implement the new medical device 2.3% excise tax. Medical device tax experts discuss how to implement these tax changes. Interact in educational sessions and collaborative lessons, and discuss with other industry affiliates concerns with the medical device excise tax. Medical device tax leaders navigate you through these tax changes by identifying key issues such as: identifying taxable medical devices; taxable and non-taxable uses; combination products; bundled services; exemptions; reporting; exclusions; rebates; payment; penalties; accounting systems; and ruling guidance. Visit MTLI online for more information. LinkedInFacebookTwitterEmail this Story
  • Join the AdvaMed-MTLI LinkedIn group!
    Build close relationships with member companies, both small and large, and receive an intimate understanding of the key issues affecting innovation, access and the bottom line. Interact in discussions that leverage the leadership and expertise of the medical technology industry. This social group is full of key stakeholders, influencers and industry thought leaders as well as regulatory and policy experts from the FDA and CMS. Aside from practical learning opportunities, this LinkedIn group provides the premier opportunity to network with key players from virtually every aspect of the industry. Link to the AdvaMed MTLI LinkedIn group page. LinkedInFacebookTwitterEmail this Story
 
Learn more about AdvaMed ->About AdvaMed | Join | Courses | Events | Newsroom

 
Position TitleCompany NameLocation
Sales Area Manager/Sales Rep of Neurovascular Intervention ProductsAsahi Intecc USA, Inc.Any location in US, CA
Compliance Consultant 2DJO GlobalVista, CA
Accreditation ManagerAmerican Association of Tissue BanksMcLean, VA
REGULATORY AFFAIRS SPECIALISTMasimo CorporationIrvine, CA
Director, Health Care ComplianceRTI BiologicsAlachua, FL
Manager, HCL Regulatory & Quality ComplianceOwens & MinorLouisville, KY
Director of Global Infrastructure - 002196Edwards LifesciencesIrvine, CA
DIR OPERATIONS, Milpitas Site - 130000007RAbbott San Jose, CA
Engineer, Process DevelopmentArthroCare CorporationIrvine, CA
Biostatistician - Post Market Surveillance Johnson & JohnsonRaynham, MA
Legal Counsel IIMedtronic, Inc.Minneapolis, MN or Washington, DC, United States
Click here to view more job listings.

  SmartQuote 
The man who insists upon seeing with perfect clearness before he decides, never decides. Accept life, and you must accept regret."
--Henri Frédéric Amiel,
Swiss philosopher, poet and critic


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
Job Board:  Jackie Basso (202) 407-7871
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent AdvaMed SmartBrief Issues:   Lead Editor:  Lisa Gough
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information